查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1638738

複雜區域疼痛症候群 (CRPS) 市場機會、成長促進因素、產業趨勢分析與預測 2024 - 2032 年

Complex Regional Pain Syndrome (CRPS) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球複雜區域疼痛症候群 (CRPS) 市場價值為 1.09 億美元，預計 2024 年至 2032 年複合年成長率為 2.4%。疼痛狀況，以及對個人化治療方法的日益關注。

製藥和生物技術公司正在積極開發 CRPS 特異性療法，旨在減少症狀的持續時間和嚴重程度。尖端的診斷技術可以更早、更準確地識別 CRPS，從而加快干預措施並改善結果。非侵入性診斷影像和標靶藥物治療變得越來越普遍，從而可以採用個人化方法來解決每位患者獨特的病情和疼痛狀況。

CRPS 市場按疾病類型分為 CRPS I、CRPS II 和 CRPS-NOS，其中 CRPS I（也稱為反射性交感神經營養不良）在 2023 年佔據 9120 萬美元的重要佔有率。 CRPS I 發生在受傷或患病後，但受影響區域沒有直接神經損傷。診斷意識的不斷提高和進步正在刺激對有效治療的需求，進一步推動市場成長。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 1.09 億美元
預測值 1.342 億美元
複合年成長率 2.4%

從治療類型來看，市場分為藥物和治療，到2023年，藥物細分市場將佔據66.1%的可觀佔有率。常用藥物包括非類固醇抗發炎藥、皮質類固醇、抗驚厥藥和雙磷酸鹽。此外，藥物治療的進步，包括新的藥物類別和神經阻斷技術，正在擴大選擇並推動改善患者的治療結果。

美國複雜區域疼痛症候群市場預計將以2.3% 的複合年成長率成長，到2032 年將達到4,980 萬美元。增加的手術和意外發生率受傷。此外，對研究的大量投資正在促進疼痛管理的創新，特別是透過神經刺激和針對性治療。美國政府的措施也透過促進改善疼痛管理實踐和減少鴉片類藥物依賴的努力來支持市場擴張，從而推進該地區的 CRPS 治療方案。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • CRPS 盛行率增加
      • 疼痛管理療法的進展
      • 意識和診斷率不斷提高
    • 產業陷阱與挑戰
      • 治療費用高
      • 現有療法的潛在副作用
  • 成長潛力分析
  • 監管環境
  • 未來市場趨勢
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：依疾病類型，2021-2032 年

  • 主要趨勢
  • CRPS一期
  • CRPS II
  • CRPS一NOS

第 6 章：市場估計與預測：依處理方式，2021-2032 年

  • 主要趨勢
  • 藥物
    • 止痛藥
    • 抗憂鬱藥
    • 皮質類固醇
    • 鴉片類藥物
    • 其他藥物
  • 治療
    • 物理治療
    • 鞘內藥物泵
    • 脊髓刺激
    • 手術交感神經切除手術
    • 其他療法

第 7 章：市場估計與預測：按管理途徑，2021-2032 年

  • 主要趨勢
  • 口服
  • 可注射
  • 其他給藥途徑

第 8 章：市場估計與預測：依最終用途，2021-2032 年

  • 主要趨勢
  • 醫院
  • 診所
  • 其他最終用戶

第 9 章：市場估計與預測：按地區，2021-2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：公司簡介

  • Abbott Laboratories
  • AbbVie
  • Averitas Pharma
  • Boston Scientific
  • Collegium Pharmaceutical
  • Eli Lilly and Company
  • Mallinckrodt Pharmaceuticals
  • Medtronic
  • Nevro
  • Pfizer
  • Sandoz
  • Teva Pharmaceutical
簡介目錄
Product Code: 12148

The Global Complex Regional Pain Syndrome (CRPS) Market was valued at USD 109 million in 2023 and is projected to grow at a CAGR of 2.4% from 2024 to 2032. Growth in this market is largely driven by the advancements in diagnostic technologies, rising prevalence of chronic pain conditions, and an increasing focus on personalized treatment approaches.

Pharmaceutical and biotechnology companies are actively developing CRPS-specific therapies aimed at reducing the duration and severity of symptoms. Cutting-edge diagnostic technologies enable earlier and more accurate identification of CRPS, leading to faster interventions and improved outcomes. Non-invasive diagnostic imaging and targeted pharmacological treatments are becoming more prevalent, allowing for a personalized approach that addresses each patient's unique condition and pain profile.

The CRPS market is segmented by disease type into CRPS I, CRPS II, and CRPS-NOS, with CRPS I, also known as Reflex Sympathetic Dystrophy, accounting for a significant share of USD 91.2 million in 2023. Representing approximately 90% of CRPS cases, CRPS I occurs following an injury or illness without direct nerve damage to the affected area. Growing awareness and advancements in diagnostics are spurring demand for effective treatments, further propelling market growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$109 Million
Forecast Value$134.2 Million
CAGR2.4%

In terms of treatment type, the market is divided into medication and therapy, with the medication segment holding a substantial share of 66.1% in 2023. Medications are essential for pain relief and symptom management, improving the quality of life for CRPS patients. Commonly used drugs include NSAIDs, corticosteroids, anticonvulsants, and bisphosphonates. Additionally, advancements in pharmacological treatments, including new drug classes and nerve block techniques, are expanding options and driving improved patient outcomes.

The U.S. complex regional pain syndrome market is expected to grow at a CAGR of 2.3%, reaching USD 49.8 million by 2032. Factors contributing to this growth include a high prevalence of chronic pain conditions, robust healthcare infrastructure, and increasing rates of surgeries and accidental injuries. Furthermore, substantial investment in research is fostering innovation in pain management, particularly through neurostimulation and targeted treatments. Government initiatives in the U.S. also support market expansion by promoting improved pain management practices and efforts to reduce opioid dependence, advancing CRPS treatment options in the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of CRPS
      • 3.2.1.2 Advancements in pain management therapies
      • 3.2.1.3 Rising awareness and diagnosis rates
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Potential side effects of available therapies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Disease Type, 2021-2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 CRPS I
  • 5.3 CRPS II
  • 5.4 CRPS-NOS

Chapter 6 Market Estimates & Forecast, By Treatment, 2021-2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Medication
    • 6.2.1 Analgesics
    • 6.2.2 Antidepressants
    • 6.2.3 Corticosteroids
    • 6.2.4 Opioids
    • 6.2.5 Other medications
  • 6.3 Therapy
    • 6.3.1 Physical therapy
    • 6.3.2 Intrathecal drug pump
    • 6.3.3 Spinal cord stimulation
    • 6.3.4 Surgical sympathectomy
    • 6.3.5 Other therapies

Chapter 7 Market Estimates & Forecast, By Route of Administration, 2021-2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Other routes of administration

Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Other end users

Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 MEA
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 AbbVie
  • 10.3 Averitas Pharma
  • 10.4 Boston Scientific
  • 10.5 Collegium Pharmaceutical
  • 10.6 Eli Lilly and Company
  • 10.7 Mallinckrodt Pharmaceuticals
  • 10.8 Medtronic
  • 10.9 Nevro
  • 10.10 Pfizer
  • 10.11 Sandoz
  • 10.12 Teva Pharmaceutical